Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | XBP1 | P17861 | 4/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 3/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 1.00 |
| ▸ | TERT | O14746 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Helenalin SCHEMBL10099625 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Helenalin SCHEMBL161593 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Helenalin SCHEMBL31237389 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Helenalin SCHEMBL10132557 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Helenalin SCHEMBL11030579 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Mexicanin I SCHEMBL17238871 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| SCHEMBL15497257 | 0.90 | MAPT (0.81) | MAPTRAB9ANPC1HTTXBP1 | |
| SCHEMBL26240747 | 0.90 | MAPT (0.81) | MAPTRAB9ANPC1HTTXBP1 | |
| Angustibalin SCHEMBL509228 | 0.84 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 | |
| Bigelovin SCHEMBL29349709 | 0.84 | MAPT (1.00) | MAPTRAB9ANPC1HTTXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4631513-A1 | OPHTHALMIC FORMULATION FOR TOPICAL USE CONTAINING HELENALIN, 11A,13-DIHYDRO HELENALIN AND FLAVONOIDS FROM ARNICA MONTANA EXTRACT AND SODIUM HYALURONATE, AND USE THEREOF BY HUMANS TO TREAT DRY EYE SYNDROME | Centro de Retina Médica Y Quirúrgica, S.C. (MX) | 2025-10-15 | — | — | EP | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| WO-2025071390-A1 | LIPID-BASED FORMULATION CONTAINING HELENALIN FOR TOPICAL OPHTHALMIC USE WITH APPLICATION IN THE MODULATION OF THE INFLAMMATORY PROCESS OF THE OCULAR SURFACE AND IN THE TREATMENT OF DRY EYE | CENTRO DE RETINA MÉDICA Y QUIRÚRGICA, S.C. (MX) | 2025-04-03 | — | — | WO | claimed |
| US-20240269196-A1 | RESPIRATORY TREATMENTS USING SALMONID OIL COMPOSITIONS | HOFSETH BIOCARE ASA (NO) | 2024-08-15 | — | — | US | claimed |
| WO-2024123165-A1 | OPHTHALMIC FORMULATION FOR TOPICAL USE CONTAINING HELENALIN, 11Α,13-DIHYDRO HELENALIN AND FLAVONOIDS FROM ARNICA MONTANA EXTRACT AND SODIUM HYALURONATE, AND USE THEREOF BY HUMANS TO TREAT DRY EYE SYNDROME | CENTRO DE RETINA MÉDICA Y QUIRÚRGICA, S.C. (MX) | 2024-06-13 | — | — | WO | claimed |
| EP-4157458-B1 | TRIARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR TREATING CANCER | INST NAT SANTE RECH MED (FR) | 2024-04-17 | — | — | EP | claimed |
| EP-1435877-A1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | Hemoteq GmbH (DE) | 2004-07-14 | — | — | EP | claimed |
| US-20040115289-A1 | Cosmetic or medicinal composition containing sesquiterpene lactone or the like for treating hair -growth related disorders, and preparation method | IMD (FR) | 2004-06-17 | — | — | US | claimed |
| WO-2003094990-A1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2003-11-20 | — | — | WO | claimed |
| WO-2003034944-A1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | HEMOTEQ GMBH (DE) | 2003-05-01 | — | — | WO | claimed |
| US-20020076452-A1 | Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 | ASHNI NATURACEUTICALS, INC. | 2002-06-20 | — | — | US | claimed |
| US-20020077350-A1 | Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2 | ASHNI NATURACEUTICALS, INC. | 2002-06-20 | — | — | US | claimed |
| US-20020077299-A1 | Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 | META PROTEOMICS, LLC | 2002-06-20 | — | — | US | claimed |
| WO-2002009698-A1 | COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 | ASHNI NATURACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| WO-1998038971-A1 | THERAPEUTIC COMPOSITION AND METHOD FOR TREATING SKIN USING CENTIPEDA CUNNINGHAMI EXTRACT | BIO-BOTANICA, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| US-5804206-A | PROVIDING PLANT MATERIAL OF CENTIPEDA GENUS IN POWDER FORM, SEQUENTIALLY MACERATING AND EXTRACTING WITH PLURALITY OF AQUEOUS/ETHANOLIC SOLVENTS OF DIFFERENT CONCENTRATION, COMBINING SOLUTIONS | BIO-BOTANICA, INC. (US) | 1998-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | CDC42, BMP4, TPMT | MAPT 1997/4885RAB9A 688/4885NPC1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.